VYKAT XR — Competitive Intelligence Brief

VYKAT XR (VYKAT XR) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium supplement. Area: Electrolyte replacement / Internal Medicine.

marketed Potassium supplement Potassium ion (K+) Electrolyte replacement / Internal Medicine Small molecule

Target snapshot

VYKAT XR (VYKAT XR) — Soleno Therapeutics, Inc.. VYKAT XR is a sustained-release formulation of potassium that provides controlled delivery of potassium to treat hypokalemia.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
VYKAT XR TARGET	VYKAT XR	Soleno Therapeutics, Inc.	marketed	Potassium supplement	Potassium ion (K+)
Chlorthalidone with potassium chloride	Chlorthalidone with potassium chloride	Brigham and Women's Hospital	marketed	Thiazide-like diuretic with potassium supplement	Sodium-chloride cotransporter (NCC)
Hydrochlorothiazide + potassium	Hydrochlorothiazide + potassium	Brigham and Women's Hospital	marketed	Thiazide diuretic with potassium supplement	Sodium-chloride cotransporter (NCC); potassium ion channels
KALOMIN™ Tab.	KALOMIN™ Tab.	Korea United Pharm. Inc.	phase 3	Potassium supplement / Electrolyte replacement	Potassium ion (K+)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium supplement class)

1. Soleno Therapeutics, Inc. · 1 drug in this class